评论 11
过滤器:
评分
语言
种类:
最近的
T
9 几个月前

The products offered by Sparingvision are exceptio...

The products offered by Sparingvision are exceptional. I'm extremely satisfied with my purchase. The customer service team was prompt and helpful in addressing my queries. Overall, a great experience!

C
10 几个月前

Sparingvision provides excellent products and serv...

Sparingvision provides excellent products and services. I'm extremely satisfied with my purchase and the customer service I received. The team was very helpful in answering all my questions.

J
1年以前

I had a great experience with Sparingvision. Their...

I had a great experience with Sparingvision. Their website is user-friendly and provides all the necessary information about their products. The customer service team was very helpful in answering all my questions. Overall, I am very satisfied with their services.

A
1年以前

I had a wonderful experience with this company. Th...

I had a wonderful experience with this company. Their products are amazing and have made a significant difference in my life. The customer service team was very helpful and responsive. I highly recommend Sparingvision!

C
1年以前

I recently purchased products from Sparingvision a...

I recently purchased products from Sparingvision and I'm absolutely thrilled with my purchase! 😃 The quality is outstanding and the customer service team was amazing. I highly recommend them!

E
1年以前

Sparingvision offers a wide range of high-quality ...

Sparingvision offers a wide range of high-quality products for vision care. Their website is easy to navigate and the ordering process was smooth. I'm happy with my purchase and would definitely recommend them to others.

关于Sparingvision

Sparingvision:用基因组药物革新眼部疾病治疗

Sparingvision 是一家领先的基因组药物公司,正在改变眼部疾病的治疗方式。该公司处于医学新时代的前沿,单一基因校正疗法已不足以解决复杂的遗传疾病。 Sparingvision 的使命是尽快为受遗传性视网膜疾病 (IRD) 影响的患者提供创新治疗,无论其遗传原因如何。

遗传性视网膜疾病 (IRD) 是一组罕见的遗传性疾病,会影响视网膜,导致进行性视力丧失和失明。这些疾病可能由 200 多个基因中的任何一个突变引起,这使得它们极难用传统方法治疗。 Sparingvision 的方法涉及使用基因组药物同时靶向多个基因,为患者提供更全面的解决方案。

该公司的主要候选产品 SPVN06 是一种基因疗法,旨在治疗由 USH2A 基因突变引起的 IRD。该基因约占所有 IRD 病例的 30%,并且众所周知,传统疗法难以靶向该基因。 SPVN06 使用了一种称为光遗传学的创新方法,该方法涉及将光敏蛋白引入因疾病相关突变而丧失功能的视网膜细胞中。

光遗传学在临床前研究中显示出巨大的前景,并有可能恢复晚期 IRD 患者的视力。 Sparingvision计划于2021年启动SPVN06的临床试验,并希望尽快将这一突破性疗法推向市场。

除了 SPVN06,Sparingvision 还开发了其他几个项目,旨在治疗由各种基因突变引起的不同类型的 IRD。该公司的产品线包括专为眼部疾病设计的基因疗法和小分子药物。

Sparingvision 由 Stéphane Boissel 于 2017 年创立,他是一位经验丰富的生物技术高管,在该行业拥有超过 20 年的经验。公司总部位于法国巴黎,拥有一支世界一流的科学家和研究人员团队,致力于推进基因组医学领域的发展。

Sparingvision 在眼部疾病治疗方面的创新方法已经引起了投资者和行业专家的极大关注。 2020年,该公司在由4BIO Capital和UPMC Enterprises领投的A轮融资中筹集了4450万欧元。这笔资金将用于推进 Sparingvision 的管道项目,并使其疗法更接近市场。

总之,Sparingvision 是一家开创性的基因组药物公司,正在彻底改变我们治疗眼部疾病的方式。凭借其创新的基因治疗和光遗传学方法,该公司有望在解决长期以来被认为无法治愈的复杂遗传疾病方面取得重大进展。随着 Sparingvision 继续推进其管道项目,它为世界各地受 IRD 影响的患者带来了巨大希望。

已翻译